Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 3 | — | — | — | 3 |
Eczema | D004485 | HP_0000964 | L30.9 | — | 3 | — | — | — | 3 |
Dermatitis | D003872 | HP_0011123 | L30.9 | — | 3 | — | — | — | 3 |
Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | ADRIFORANT |
INN | adriforant |
Description | Adriforant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target histamine H3 receptor and histamine H4 receptor. |
Classification | Small molecule |
Drug class | histamine H4 receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN[C@@H]1CCN(c2cc(NCC3CC3)nc(N)n2)C1 |
PDB | — |
CAS-ID | 943057-12-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1915540 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | D65H9YE9VU (ChemIDplus, GSRS) |